ANALGESIC EFFECT OF SALMON-CALCITONIN IN OSTEOPOROTIC VERTEBRAL FRACTURES - A DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL-STUDY

被引:138
作者
LYRITIS, GP
TSAKALAKOS, N
MAGIASIS, B
KARACHALIOS, T
YIATZIDES, A
TSEKOURA, M
机构
[1] Th. Garofalidis Research Centre, University of Athens, KAT Hospital, Kifissia
关键词
OSTEOPOROSIS; VERTEBRAL CRUSH FRACTURES; PAIN; MOBILIZATION; SALMON CALCITONIN; URINARY CALCIUM; URINARY HYDROXYPROLINE;
D O I
10.1007/BF02555844
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Back pain due to vertebral collapse is the main symptom of postmenopausal osteoporosis. The clinical picture in these crush fractures varies, depending on the type and the location of fracture, but in general, a new vertebral crush fracture gives rise to severe pain that immobilizes the patient and necessitates bedrest. In this double-blind controlled clinical trial, 56 patients who had recently (within the last 3 days) suffered an osteoporotic vertebral fracture were hospitalized for a period of 14 days. Salmon calcitonin (100 IU) or placebo injections were given daily. Pain was rated daily on a 10-point scale by the same observers. Blood and urinary parameters were also evaluated. The results showed a significant (P < 0.001) difference in pain intensity between the calcitonin group and the placebo group. This beneficial effect was generally apparent from the second day of treatment onward, and over the following 2 weeks, the patients were able to sit and stand, and gradually started to walk again. A significant decrease in urinary hydroxyproline and urinary calcium was also noted in the calcitonin group. It is concluded that calcitonin exerts a beneficial effect on back pain following a vertebral crush fracture.
引用
收藏
页码:369 / 372
页数:4
相关论文
共 15 条
[1]   SYNTHETIC HUMAN CALCITONIN IN REFRACTORY PAGETS-DISEASE OF BONE [J].
ALTMAN, RD ;
COLLINSYUDISKAS, B .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (07) :1305-1308
[2]  
DOURY P, 1980, RHEUMATOLOGIE, V22, P113
[3]   SUB-ARACHNOID INJECTION OF SALMON-CALCITONIN INDUCES ANALGESIA IN MAN [J].
FRAIOLI, F ;
FABBRI, A ;
GNESSI, L ;
MORETTI, C ;
SANTORO, C ;
FELICI, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 78 (03) :381-382
[4]  
GENNARI C, 1985, CALCITONIN 1984, P183
[5]  
GENNARI C, 1987, INT S OSTEOPOROSIS, P1256
[6]   LONG-TERM CALCITONIN THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS [J].
GRUBER, HE ;
IVEY, JL ;
BAYLINK, DJ ;
MATTHEWS, M ;
NELP, WB ;
SISOM, K ;
CHESNUT, CH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1984, 33 (04) :295-303
[7]  
LAM KS, 1988, OSTEOPOROSIS EPIDEMI, P81
[8]  
LEVERNIEUX J, 1984, CALCITONIN 1984 SELE
[9]  
LYRITIS GP, CLIN RHEUMATOL S, V8, P66
[10]  
LYRITIS GP, 1984, CALCITONIN 1984, P107